Table 1.
Demographic and Baseline Characteristics of the Study Patients*
| Characteristics | AHBV-ALF (n=60) | CHBV-ALF (n=27) | P value# | CHBV-ALF-non-immunosuppressed (n=9) | P value¥ |
|---|---|---|---|---|---|
| Age (yr) | 36 (17–64) | 53 (33–71) | <0.001 | 60 (46–69) | <0.001 |
| Race | |||||
| African American | 37 (22/60) | 22 (6/27) | <0.001 | 0 | <0.001 |
| Asian | 3 (2/60) | 52 (14/27) | 67 (6/9) | ||
| Caucasian | 52 (31/60) | 22 (6/27) | 22 (2/9) | ||
| Other | 8 (5/60) | 4 (1/27) | 11 (1/9) | ||
| Female Sex | 47 (28/60) | 37 (10/27) | 0.402 | 22 (2/9) | 0.281 |
| ALT (IU/L) | 1,954 (87–11,100) | 1,008 (94–7,856) | 0.018 | 826 (117–7,774) | 0.069 |
| AST (IU/L) | 1,024 (66–9,901) | 719 (78–8,615) | 0.248 | 530 (98–7,420) | 0.250 |
| Bilirubin (mg/dL) | 18.4 (3.6–62.4) | 20.2 (5.7–36.0) | 0.319 | 21.4 (7.5–30.4) | 0.392 |
| Albumin (g/dL) | 2.8 (1.7–4.0) | 2.5 (1.7–3.3) | 0.006 | 2.4 (2.0–3.3) | 0.056 |
| INR | 2.9 (1.2–20.1) | 3.2 (0.9–10.3) | 0.456 | 2.7 (0.9–9.4) | 0.679 |
| Hepatic Coma Grade | |||||
| I & II | 48 (29/60) | 41 (11/27) | 0.511 | 33 (3/9) | 0.489 |
| III & IV | 52 (31/60) | 59 (16/27) | 67 (6/9) | ||
| Creatinine (mg/dL) | 1.1 (0.4–8.6) | 1.1 (0.6–10.5) | 0.508 | 1.8 (0.6–6.6) | 0.269 |
| Days from Jaundice to Onset of Hepatic Coma | 5 (0–46) | 9.5 (0–28) | 0.277 | 13 (1–28) | 0.202 |
| HBsAg Negativity | 20 (12/60) | 0 (0/27) | 0.015 | 0 (0/9) | 0.342 |
| HBeAg Positivity | 26 (15/57) | 27 (7/26) | 0.954 | 11 (1/9) | 0.436 |
| Anti-HBs Positivity | 28 (17/60) | 15 (4/27) | 0.173 | 11 (1/9) | 0.428 |
| HBV Genotype | |||||
| A | 51 (24/47) | 29 (7/24) | 0.003 | 13 (1/8) | <0.001 |
| B | 9 (4/47) | 46 (11/24) | 88 (7/8) | ||
| C | 4 (2/47) | 8 (2/24) | 0 | ||
| D | 30 (14/47) | 17 (4/24) | 0 | ||
| Other | 6 (3/47) | 0 | 0 | ||
| HBV Basal Core Promoter Mutations (A1762T/G1764A) | 31 (15/48) | 25 (5/20) | 0.606 | 29 (2/7) | >0.999 |
| HBV Pre-Core Mutation (G1896A) | 21 (10/47) | 50 (10/20) | 0.019 | 86 (6/7) | 0.002 |
| HBV Pre-Core ± Basal Core | 40 (19/47) | 60 (12/20) | 0.141 | 86 (6/7) | 0.041 |
| Promoter Mutations | |||||
| HBV Viral Load - log10 (IU/mL) | 3.9 (0.0–8.1) | 5.2 (2.0–8.7) | 0.025 | 3.8 (2.5–8.7) | 0.982 |
| IgM Anti-HBc (Index value) | 88.5 (0–1,120) | 1.3 (0–750) | <0.001 | 1.9 (0–28.9) | <0.001 |
| N-acetylcysteine Treatment | 51 (30/59) | 15 (4/27) | 0.002 | 44 (4/9) | >0.999 |
| Acetaminophen Use Mentioned | 80 (28/35) | 60 (6/10) | 0.228 | 67 (2/3) | 0.519 |
| Alcohol Use | 43 (25/58) | 31 (8/26) | 0.285 | 33 (3/9) | 0.724 |
| Nucleoside (tide) Analogues Use | 53 (31/59) | 78 (21/27) | 0.026 | 89 (8/9) | 0.068 |
| Spontaneous Survival | 33 (20/60) | 11 (3/27) | 0.030 | 11 (1/9) | 0.258 |
| Overall 3-week Survival | 72 (43/60) | 44 (12/27) | 0.015 | 44 (4/9) | 0.132 |
*
Continuous data are shown as median (range) and categorical data are % (numerator/denominator).
#
Comparison between AHBV-ALF vs. Overall CHBV-ALF
¥
Comparison between AHBV-ALF vs. CHBV-ALF without immunosuppression (CHBV-ALF)